NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

aTyr Pharma, Inc. (ATYR) Stock Analysis

aTyr Pharma, Inc. (ATYR) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ATYR

$0.17

−$0.00 (−0.58%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ATYR with… →

ATYR Key Statistics

As of Oct 21, 2026
Trading
Open
$0.17
Previous Close
$0.17
Day's Range
0.17–0.18
52-Week Range
0.17–1.11
Volume
1.21M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.91
Valuation
Market Cap
$16.90M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
88.95
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.62
Financials (FY)
Revenue (FY)
$190.00K−19.15%
Net Income (FY)
−$74.12M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
98.09M
1-Year Return
−83.27%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
3.28M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ATYR closed at $0.17, −83.27% over 1 year.

aTyr Pharma, Inc. (ATYR) has a market capitalization of $16.90M.

In fiscal 2025, ATYR reported revenue of $190.00K.

ATYR Stock Return by Calendar Year

aTyr Pharma, Inc. (ATYR) 10-year return: what $10,000 became

1 year
$10,000 $1,673
−83.27%
5 years
$10,000 $201
−97.99%
10 years
$10,000 $42
−99.58%

If you had invested $10,000 in aTyr Pharma, Inc. (ATYR) 10 years ago, at the close on October 21, 2016, it would have been worth $42 at the close on October 21, 2026: −99.58% in total, −42.09% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−77.99%
2025−78.37%
2024+156.74%
2023−35.62%
2022−70.68%
2021+92.53%
2020−6.95%
2019−39.95%
2018−85.83%
2017+62.79%
2016 (partial year)−34.85%

As of October 21, 2026.

ATYR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$190.00K−$74.12M−39,009.5%
2024$235.00K−$64.02M−27,243.8%
2023$353.00K−$50.39M−14,274.5%
2022$10.39M−$45.34M−436.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$190.00K—−$77.63M−$74.12M−39,009.5%
2024$235.00K—−$67.91M−$64.02M−27,243.8%
2023$353.00K—−$54.92M−$50.39M−14,274.5%
2022$10.39M—−$46.40M−$45.34M−436.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ATYR Valuation vs Biotechnology Median

Median of 608 stocks
MetricATYRBiotechnology medianvs median
P/S ratio88.9513.306.7x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 13 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values aTyr Pharma, Inc. (ATYR) at $16.90M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 58.

Over the past 52 weeks the price has ranged from $0.17 to $1.11. The most recent close on file for ATYR is $0.17, dated October 21, 2026. That is $0.00 (−0.58%) against the previous close. The latest close sits 4.42% above that 52-week low.

Financial Health

In fiscal 2025, aTyr Pharma, Inc. reported revenue of $190.00K. Against the prior fiscal year total of $235.00K, that is a change of −19.15%. The same year closed with a net loss of $74.12M. Trailing earnings per share are −0.62.

Across the 4 fiscal years on file, revenue moves from $10.39M in 2022 to $190.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 88.95 times revenue. On price-to-sales that is 6.7 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The trailing one-year total return is −83.27%. Measured over 10 years, that is −42.09% a year compounded. Beta against the wider market is reported at 0.91. Daily returns over the trailing 10 years annualize to a volatility of 88.78%.

Growth & Income

The record shows no dividend for ATYR.

So far in 2026 the total return is −77.99%. The strongest complete calendar year on file is 2024 at +156.74%; the weakest is 2018 at −85.83%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

aTyr Pharma, Inc. (ATYR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
aTyr Pharma, Inc. ATYR $16.90M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. aTyr Pharma, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About aTyr Pharma, Inc.

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company develops ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders; and develops and tests ATYR2810, the Company's monoclonal antibody that targets the neuropilin-2 (NRP2) receptor for the treatment of aggressive cancers. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Visit website →